On Sept. 14, 2020, Pascal Biosciences and SoRSE Technology announced they had entered into a collaborative research agreement to advance Pascal’s PAS-393 into clinical testing. Pascal and SoRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors.

SōRSE currently sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and more than 12 months’ shelf stability. Pascal and SōRSE scientists will optimize a cannabinoid formulation for human subjects and will then test the formulated PAS-393 in volunteers. SōRSE will provide $750,000 in research funding to Pascal throughout the 15-month collaboration and will pay for related research expenditures.

Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SōRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor. Dr. Gray presented scientific data in September at the 3rd Annual International Cannabinoid-Derived Pharmaceutical Conference in Boston, MA; the topic of his presentation was “Identifying and Validating Mechanism of Action In vivo/vitro.”